FOLFIRI as second-line chemotherapy for advanced pancreatic cancer: a GISCAD multicenter phase II study

被引：0

作者：

Alberto Zaniboni

Enrico Aitini

Sandro Barni

Daris Ferrari

Stefano Cascinu

Vincenzo Catalano

Giuseppe Valmadre

Domenica Ferrara

Enzo Veltri

Claudio Codignola

Roberto Labianca

机构：

[1] Fondazione Poliambulanza,Medical Oncology Unit

[2] C. Poma Hospital,Medical Oncology Unit

[3] Treviglio-Caravaggio Hospital,Medical Oncology Unit

[4] S. Paolo Hospital,Medical Oncology Unit

[5] Università Politecnica delle Marche,Medical Oncology Unit

[6] Ospedali Riuniti di Ancona,Medical Oncology Unit

[7] Ospedali Riuniti Marche Nord,Medical Oncology DH

[8] Presidio San Salvatore,Medical Oncology Unit

[9] Ospedale di Sondalo,Medical Oncology Unit

[10] Ospedale San Carlo,Department of Surgery

[11] Ospedale Don Luigi di Liegro,Medical Oncology Unit

[12] Fondazione Poliambulanza,undefined

[13] Ospedali Riuniti,undefined

来源：

Cancer Chemotherapy and Pharmacology | 2012年 / 69卷

关键词：

Pancreatic cancer; FOLFIRI; Chemotherapy; Second-line; Irinotecan;

D O I：

暂无

中图分类号：

学科分类号：

摘要：

引用

页码：1641 / 1645

页数：4

共 50 条

[31] A randomised phase II study of modified FOLFIRI.3 vs modified FOLFOX as second-line therapy in patients with gemcitabine-refractory advanced pancreatic cancer
Yoo, C.
Hwang, J. Y.
Kim, J-E
Kim, T. W.
Lee, J. S.
Park, D. H.
Lee, S. S.
Seo, D. W.
Lee, S. K.
Kim, M-H
Han, D. J.
Kim, S. C.
Lee, J-L
BRITISH JOURNAL OF CANCER, 2009, 101 (10) : 1658 - 1663
[32] Second-Line Therapy in Refractory Pancreatic Cancer. Results of a Phase II Study
Pelzer, Uwe
Stieler, Jens
Roll, Lars
Hilbig, Andreas
Doerken, Bernd
Riess, Hanno
Oettle, Helmut
ONKOLOGIE, 2009, 32 (03): : 99 - 102
[33] Phase II study of lapatinib and capecitabine in second-line treatment for metastatic pancreatic cancer
Wu, Zheng
Gabrielson, Andrew
Hwang, Jimmy J.
Pishvaian, Michael J.
Weiner, Louis M.
Zhuang, Tingting
Ley, Lisa
Marshall, John L.
He, Aiwu Ruth
CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2015, 76 (06) : 1309 - 1314
[34] A phase II study of lapatinib and capecitabine in second-line treatment of metastatic pancreatic cancer
Wu, Zheng
Marshall, John
Hwang, Jimmy J.
Pishvaian, Michael J.
Wellstein, Anton
Weiner, Louis M.
He, Aiwu Ruth
JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
[35] Phase II study of lapatinib and capecitabine in second-line treatment for metastatic pancreatic cancer
Zheng Wu
Andrew Gabrielson
Jimmy J. Hwang
Michael J. Pishvaian
Louis M. Weiner
Tingting Zhuang
Lisa Ley
John L. Marshall
Aiwu Ruth He
Cancer Chemotherapy and Pharmacology, 2015, 76 : 1309 - 1314
[36] Phase II Study of Second-line Chemotherapy With Paclitaxel, Gemcitabine, and Cisplatin for Advanced Urothelial Carcinoma
Ogawa, Masahiro
Yamamoto, Shinya
Inoue, Toru
Numao, Noboru
Yuasa, Takeshi
Masuda, Hitoshi
Fukui, Iwao
Yonese, Junji
ANTICANCER RESEARCH, 2020, 40 (03) : 1613 - 1618
[37] Gefitinib phase II study in second-line treatment of advanced esophageal cancer.
Van Groeningen, C
Richel, D
Giaccone, G
JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (14) : 319S - 319S
[38] A Phase II Study Alternating Erlotinib With Second-line mFOLFOX6 or FOLFIRI for Metastatic Colorectal Cancer
Kearney, Matthew R.
Chen, Emerson Y.
Vaccaro, Gina M.
Strother, John
Burt, Andrea
Todd, Kendra
Donovan, Jeff
Kampa-Schittenhelm, Kerstin M.
Lopez, Charles D.
ANTICANCER RESEARCH, 2019, 39 (01) : 245 - 252
[39] Second-line chemotherapy with gemcitabine-vindesine in advanced breast cancer (ABC) patients (pts): A feasibility evaluation study of GISCAD.
Barni, S
Ardizzoia, A
Poletti, P
Bernardo, A
Bonciarelli, G
Mastore, M
Bollina, R
Labianca, R
Malugani, F
Cazzaniga, M
ANNALS OF ONCOLOGY, 2000, 11 : 31 - 31
[40] Phase II study of biweekly irinotecan and cisplatin as second-line chemotherapy in pretreated patients with advanced gastric cancer.
Baek, JH
Kim, JG
Sohn, SK
Song, HS
Kwon, KY
Do, YR
Ryu, HM
Bae, SH
Park, GW
Lee, KH
JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) : 325S - 325S

← 1 2 3 4 5 →